Advertisement
The poster (Abstract #7051) entitled "A double blind placebo-controlledrandomized phase III study of high-dose continuous infusion cytosinearabinoside (araC) with or without VNP40101M in patients with first relapse ofAML" will be presented at McCormick Place, South Hall A1, Board 38E from 8:00a.m. to 12:00 p.m. on Saturday, May 31, 2008. A copy of the poster will beavailable on Vion Pharmaceuticals' website, www.vionpharm.com, on May 31, 2008at 7:00 a.m. Eastern Time.
Advertisement
The poster (Abstract #7025) entitled "A phase II study of VNP40101M inelderly patients with de novo poor risk AML" will be presented at McCormickPlace, Room E450a, Board 15 from 2:00 p.m. to 6:00 p.m. on Monday June 2,2008. A poster discussion will take place at 5:30 p.m. in Room E354a. A copyof the poster will be available on Vion Pharmaceuticals' website,www.vionpharm.com, on June 2, 2008 at 1:00 p.m. Eastern Time.
About Vion
Vion Pharmaceuticals, Inc. is committed to extending the lives andimproving the quality of life of cancer patients worldwide by developing andcommercializing innovative cancer therapeutics. Vion has two agents inclinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, isbeing evaluated in a Phase II pivotal trial as a single agent in elderlypatients with previously untreated de novo poor-risk acute myelogenousleukemia. Clinical trials of Cloretazine(R) (VNP40101M) with cytarabine inacute myelogenous leukemia, with temozolomide in brain tumors, and with stemcell transplantation in advanced hematologic malignancies, are also beingconducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, isbeing evaluated in clinical trials sponsored by the National Cancer Institute.For additional information on Vion and its product development programs, visitthe Company's Internet web site at www.vionpharm.com.
This news release contains forward-looking statements. Such statements aresubject to certain risk factors which may cause Vion's plans to differ orresults to vary from those expected, including Vion's potential inability toobtain regulatory approval for its products, particularly Cloretazine(R)(VNP40101M), delayed or unfavorable results of drug trials, the possibilitythat favorable results of earlier preclinical studies, clinical trials orinterim clinical trial data are not predictive of safety and efficacy resultsin later or final clinical trials, the need for additional research andtesting, the inability to manufacture product, the potential inability tosecure external sources of funding to continue operations, the inability toaccess capital and funding on favorable terms, continued operating losses andthe inability to continue operations as a result, the possible delisting ofthe Company's common stock from the NASDAQ Capital Market and a variety ofother risks set forth from time to time in Vion's filings with the Securitiesand Exchange Commission, including but not limited to the risks attendant tothe forward-looking statements included under Item 1A, "Risk Factors" inVion's Form 10-K for the year ended December 31, 2007 and Form 10-Q for thequarter ended March 31, 2008. In particular, there can be no assurance as tothe results of any of the Vion's clinical trials, that any of these trialswill continue to full accrual, or that any of these trials will not bediscontinued, modified, delayed or ceased altogether. Except in specialcircumstances in which a duty to update arises under law when prior disclosurebecomes materially misleading in light of subsequent events, Vion does notintend to upd
